News

Kyle, Nathaniel and Vanessa are here to inspire you to join us at the 2023 Gutsy Walk!

Kyle, Nathaniel and Vanessa are here to inspire you to join us at the 2023 Gutsy Walk!

Crohn’s and Colitis Canada Responds to Ontario’s Decision to Proceed with Non-Medical Switch Policy

Crohn’s and Colitis Canada Responds to Ontario’s Decision to Proceed with Non-Medical Switch Policy

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

 1 2 3 4 5 6 7 8 9 10 

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest